To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo The new GLP-1 pills are likely to boost consumer demand for these popular weight-loss drugs. But it could also signal bad news for employees who want their employer-sponsored health insurance plan to foot the bill. Novo Nordisk, the maker of Wegovy, introduced its GLP-1 pill for weight loss in early January, while Eli Lilly's pill, Foundayo , began shipping in April. While many industry watchers were hoping the oral